6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Published on
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________________________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For
the
month of June, 2006.
Commission
File Number ________________
Novogen
Limited
(Translation
of registrant’s name into English)
140
Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F
x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a
Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7):
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form
6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes o No
o
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
Novogen
Limited
(Registrant)
/s/
Ron Erratt
Ronald
Lea Erratt
Company
Secretary
Date
15 June, 2006
ASX
& MEDIA RELEASE
15
JUNE, 2006
AUSTRIAN
COURT UPHOLDS NOVOGEN
PATENT FOR RED CLOVER ISOFLAVONES
The
Vienna Commercial Court has found that Novogen’s isoflavone invention and patent
is novel and inventive.
The
Court
found APOtrend’s menopause product Vitalady infringed Novogen’s patent and the
provisional injunction against Vitalady has been upheld. As a preliminary
question the Court assumed the validity of Novogen’s patent.
APOtrend
is now required to retract all infringing Vitalady products from retail,
wholesale and any other channels of sale.
Novogen’s
representative in Austria, Renate Moser, said that the Court decision was
also a
confirmation of the inventiveness of Novogen’s patent.
“The
Vienna Commercial Court findings are a reflection of similar patent success
Novogen has experienced in Canada and USA. Novogen will continue to protect
and
enforce its intellectual property rights around the world for the benefit
of
users of nutritional supplements”, Moser said.
The
Company has provided a guarantee to the value of 250.000 Euros with the
Austrian
Court to confirm its commitment to the ongoing enforcement process.
Novogen
believes the protection of Intellectual Property is a fundamental step
in the
development of high quality nutritional supplements with standardised active
ingredients that are clinically supported for the benefit of consumers,
health
care professionals and retailers.
About
Novogen
Novogen
is an Australian based biotechnology company in the business of research
and
development of drugs derived from its phenolic technology platform. The
Company
manages its research and development programs utilising the expertise and
clinical research capabilities of universities and hospitals in Australia,
USA
and Europe. Novogen’s drug program is researching and developing compounds for
the treatment of cancer, cardiovascular disease and osteoarthritis. To
date
Novogen has had 51 patents granted and a further 240 patents are pending.
Novogen’s
consumer business has conducted the largest and most comprehensive isoflavone
clinical testing program in the world. Novogen’s consumer brands Promensil, and
Trinovin are clinically supported, natural products for women and men’s health.
Patents supporting Novogen’s consumer brands have been granted in USA, Europe,
Canada and Australia.
Further
information on the Novogen Group can be found at www.novogen.com.
Under
U.S. law, a new drug cannot be marketed until it has been investigated
in
clinical trials and approved by the FDA as being safe and effective for
the
intended use. Statements included in this press release that are not historical
in nature are "forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
You
should be aware that our actual results could differ materially from those
contained in the forward-looking statements, which are based on management's
current expectations and are subject to a number of risks and uncertainties,
including, but not limited to, our failure to successfully commercialize
our
product candidates; costs and delays in the development and/or FDA approval,
or
the failure to obtain such approval, of our product candidates; uncertainties
in
clinical trial results; our inability to maintain or enter into, and the
risks
resulting from our dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization, marketing,
sales
and distribution of any products; competitive factors; our inability to
protect
our patents or proprietary rights and obtain necessary rights to third
arty
patents and intellectual property to operate our business; our inability
to
operate our business without infringing the patents and proprietary rights
of
others; general economic conditions; the failure of any products to gain
market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and
one-time events. We do not intend to update any of these factors or to
publicly
announce the results of any revisions to these forward-looking
statements.
--ISSUED
FOR: NOVOGEN
LIMITED
LISTINGS: ASX
(CODE NRT), NASDAQ (CODE NVGN).
FOR
FURTHER CHRISTOPHER
NAUGHTON, MANAGING DIRECTOR, NOVOGEN LIMITED
INFORMATION: TEL
(02) 9878 0088 http://www.novogen.com
ISSUED
BY : WESTBROOK
COMMUNICATIONS
CONTACT:
DAVID REID TEL (02) 9231 0922 OR 0417 217 157